Navigation Links
MD Anderson, Foundation Medicine, team up to improve targeted therapies in metastatic disease
Date:8/14/2014

The University of Texas MD Anderson Cancer Center announced today an alliance with Cambridge, MA-based Foundation Medicine. The teams are opening a randomized-controlled trial to determine whether targeted therapies selected based on tumor molecular profiling compared with treatment not selected on this basis results in longer progression-free survival in patients with advanced disease.

This study aims to demonstrate that targeted therapies matched to individual patients can improve outcomes. This would support the broader use of this therapeutic strategy across all types of cancers, not just in select ones for whom existing diagnostic and treatment options were insufficient.

Known as the IMPACT2 (Initiative for Molecular Profiling and Advanced Cancer Therapy) trial, the study builds on promising results from the first IMPACT trial, presented at the American Society of Clinical Oncology's Annual Meeting in 2011.

That previous study found that of the 1,144 patients enrolled, 40 percent had an identifiable genomic alteration. This early data enabled numerous cancer centers and practicing oncologists to begin using this approach as standard practice to benefit select groups of metastatic patients for whom targeted therapies were medically necessary.

By matching specific gene alterations to therapies, 27 percent of patients responded, compared to 5 percent with an unmatched treatment, and progression-free survival was appreciably longer in the matched group.

Led by Apostolia Maria Tsimberidou, M.D., Ph.D., the IMPACT2 study is an effort to further validate the earlier findings and results of non-randomized studies while engaging industry leaders in genomic profiling. Recognized as precision medicine, MD Anderson physician-scientists believe the approach will lend itself to better patient outcomes. It will also help match patients for clinical trials of new medications, as well as reduce the cost and time necessary to conduct those trials.

"This is a collaborative and institutional-wide effort to improve patient care and accelerate the drug development process," Tsimberidou said. "If the results of IMPACT1 are confirmed, cancer treatment will be transformed and comprehensive molecular profiling will become the standard of care."

The trial is made possible through collaboration with Foundation Medicine, which will provide support with their validated, comprehensive genomic profiling assay, FoundationOne, which detects all classes of genomic alterations in solid tumors across 315 cancer-related genes, as well as 28 other genes often rearranged in cancer. It's expected that more patients will be eligible for targeted therapies given the more comprehensive nature of FoundationOne versus the molecular testing used in IMPACT1.

"Based on the IMPACT1 data, a validated, comprehensive profiling approach has already been adopted by many academic and community-based oncology practices. They use this approach for select groups of cancer patients for whom existing diagnostic and treatment options are inadequate, such as non-small cell lung cancer, cancer of unknown primary and rare tumors," said Vincent Miller, M.D., chief medical officer of Foundation Medicine. "This study has the potential to yield sufficient evidence necessary to support broader adoption across most newly diagnosed metastatic tumors. We're pleased to partner with MD Anderson, who is uniquely positioned to execute this study given their clinical trials expertise."

The effort brings together MD Anderson's capabilities from several departments, including Investigational Cancer Therapeutics, Thoracic/Head and Neck Medical Oncology, Genitourinary Medical Oncology, Melanoma Medical Oncology, Sarcoma Medical Oncology, Gynecologic Oncology, and Endocrine Neoplasia and Hormonal Disorders; and from several divisions, including Diagnostic Imaging, Pathology, Surgical Oncology, and Biostatistics. Physicians and researchers will be able to select eligible patients who may benefit and contribute to all aspects of the study.

Information derived from tumor profiling will be available three weeks from the start of enrollment to guide treatment decisions.

"We're pleased to collaborate with Dr. Tsimberidou and MD Anderson on this important clinical trial that's bringing the benefits of FoundationOne to patients with cancer," said Michael J. Pellini, M.D., president and CEO of Foundation Medicine. "This trial, and others like it, are helping to drive the oncology field forward at a pace never seen before, supporting the evaluation and development of targeted therapies. It will ultimately help to provide safer and more effective treatments for all patients with cancer."

"Through this effort we're partnering with a leader in genomic testing and analysis to further demonstrate how tumor profiling has the potential to improve therapies and reduce development costs," said Ferran Prat, Ph.D., J.D. and vice president of MD Anderson's Strategic Industry Ventures.


'/>"/>

Contact: William Fitzgerald
wbfitzgerald@mdanderson.org
713-792-9518
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Related medicine news :

1. UT MD Anderson, GlaxoSmithKline to collaborate on new approach to cancer immune therapy
2. Dr. James Sanderson, Jr. Of SanDentistry in Hoover, Alabama Joins the TeethWhiteningforFree.com Family
3. Sleep Apnea Treatment Becoming More Popular in New York After Long Island Dental Sleep Medicine Begins Treatment on OJ Anderson, Giants Super Bowl Champion
4. MD Anderson, MedImmune join forces to advance cancer immunotherapy
5. Kessler Foundation names Dr. John Whyte recipient of Foundations 2nd Annual DeLisa Award
6. Kessler Foundation scientist awarded $554,000 for multiple sclerosis employment research
7. Kessler Foundation researchers present at first International Congress on Cognition in MS
8. Biomedical researchers receive Hartwell Foundation awards
9. Kessler Foundation scientists present cognitive research findings at MS dual symposium
10. Damon Runyon Cancer Research Foundation awards $3.3 million to 8 top young clinical investigators
11. Actos Bladder Cancer Lawsuit Filed in Louisiana Alleging Woman Used Diabetes Medication and Contracted Bladder Cancer, Consumer Justice Foundation Reports
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
MD Anderson, Foundation Medicine, team up to improve targeted therapies in metastatic disease
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... In Madeira ... the mainland by a single drawbridge, citizens formed an organization, Madeira Beach United, to ... traffic and change the small town center to a high rise urban environment. , ...
(Date:5/26/2016)... ... May 26, 2016 , ... Women’s athletic apparel company ... second pop-up shop for three consecutive weekends. The pop-up shop is a great ... community, a community full of women who appreciate the most premium goods and ...
(Date:5/25/2016)... ... May 26, 2016 , ... The United States Food and Drug ... in both men and women. To date, the company is the first and only ... any adult who suffers with androgenetic alopecia. , “This new level of clearance ...
(Date:5/25/2016)... ... May 25, 2016 , ... Extremity ... Tennessee locations to streamline patient check-in and post visit surveys. , “The Phreesia ... patient care. It has revolutionized the check-in process for our clinic network, providing ...
(Date:5/25/2016)... ... May 25, 2016 , ... A new update to Xsens ... all by utilizing a common Wi-Fi network and a mobile device. When paired with ... location with Wi-Fi, and use a mobile device to control the recording. , ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... PUNE, India , May 25, 2016 /PRNewswire/ ... Pipeline Review, H1 2016"market research report that provides ... complete with comparative analysis at various stages, therapeutics ... route of administration (RoA) and molecule type, along ... releases. It also reviews key players involved in ...
(Date:5/24/2016)... 24, 2016   ... primären Endpunkte und demonstriert Ebenbürtigkeit bei ... ‚ausgezeichneter plus guter , ...      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) ... positive Daten von der MORA-Studie der Phase III ...
(Date:5/24/2016)... ARANZ Medical  Ltd a specialist ... has been named the Coretex Hi-Tech Emerging Company of the ... Dr Bruce Davey , CEO of ARANZ Medical says, ... good to be recognised for the work we are doing ... in 35 countries around the world from Sub-Saharan Africa through ...
Breaking Medicine Technology: